U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07120984) titled 'A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma' on July 30.
Brief Summary: The purpose of this study is to explore the safety and efficacy of the antibody-cytokine fusion protein L19TNF alone or in combination with alkylating chemotherapy in patients with recurrent IDH mutant glioma.
Study Start Date: Jan. 30, 2026
Study Type: INTERVENTIONAL
Condition:
Glioma
Intervention:
BIOLOGICAL: L19TNF
1 cycle of TNF before resection and 6 cycles after surgery
BIOLOGICAL: L19TNF and TMZ
6 cycles of 28 days with L19TNF and TMZ
B...